Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy

Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy

Currently, there are two Food and Drug Administration (FDA)-approved drugs for androgen deprivation therapy (ADT) of metastatic castration-resistant prostate cancer (mCRPC) patients: abiraterone and enzalutamide. However, our understanding of the effect of these therapies on the immune system in mCR...

Full description

Bibliographic Details
Main Authors: Sumanta K. Pal, Dayson Moreira, Haejung Won, Seok Woon White, Pryanka Duttagupta, Marc Lucia, Jeremy Jones, JoAnn Hsu, Marcin Kortylewski
Format: Article
Language:English
Published: MDPI AG 2019-04-01
Series:International Journal of Molecular Sciences
Subjects:
castration-resistant prostate cancer
abiraterone
enzalutamide
CRPC
cytokines
ADT
Online Access:https://www.mdpi.com/1422-0067/20/8/1831

Internet

https://www.mdpi.com/1422-0067/20/8/1831

Similar Items